缺血性室间隔缺损临时机械循环支持的当代结局:美国多中心分析
整体89.7%需要临时机械循环支持,ECMO组术前病情更重、干预前死亡率更高(30.0% vs 1.8%,P<.001)。接受干预者中,ECMO组住院死亡率52.4%,非ECMO组28.6%(P<.001)。
要点
- 缺血性室间隔缺损患者中89.7%需要临时机械循环支持,主动脉内球囊反搏最常用(62.4%)。
- ECMO组术前乳酸、肌酐、转氨酶更高且心室功能更差,干预前死亡率显著更高(30.0% vs 1.8%)。
- ECMO支持、乳酸≥3 mmol/L、左室射血分数<50%为死亡的独立预测因素。
核心结论
- 缺血性室间隔缺损常需临时机械循环支持,近半数使用静脉-动脉ECMO,总体结局仍严峻。
研究设计与样本
- 回顾性多中心分析,纳入2014-2023年7个美国移植中心的117例缺血性室间隔缺损患者。
主要发现
- 各中心年均病例数为1至2.5例/年。
- 整体89.7%需要临时机械循环支持,主动脉内球囊反搏最常用(62.4%),静脉-动脉ECMO使用率51.3%。
- ECMO组术前乳酸、肌酐、转氨酶更高,心室功能更差。
- 干预前死亡率ECMO组30.0% vs 非ECMO组1.8%(P<.001)。
- 接受干预者住院死亡率ECMO组52.4% vs 非ECMO组28.6%(P<.001);7例接受进阶治疗者死亡率28.6%。
关键数值与推荐
- 多因素分析显示ECMO支持需求、乳酸≥3 mmol/L、左室射血分数<50%为死亡的独立预测因素。
临床怎么用
- 对缺血性室间隔缺损合并血流动力学不稳定者,应评估临时机械循环支持指征,ECMO可用于高危患者。
- ECMO支持、高乳酸和左室射血分数降低提示死亡风险高,需强化多学科综合管理。
局限性
- 回顾性设计,样本量117例,仅来自7个移植中心,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic ventricular septal defect (VSD) remains a lethal complication of acute myocardial infarction, often requiring temporary mechanical circulatory support (tMCS) to stabilize hemodynamics. This study aimed to characterize contemporary use and outcomes of tMCS in ischemic VSD across US transplant centers. METHODS: Retrospective data from 7 centers (2014-2023) were analyzed, including 117 patients with ischemic VSD. Sixty patients received extracorporeal membrane oxygenation (ECMO group) and 57 did not (No-ECMO group). Clinical characteristics, intervention types, and outcomes were compared. RESULTS: The mean annual case per center ranged from 1 to 2.5 per year. Overall, 89.7% of patients required tMCS, most commonly intraaortic balloon pump (62.4%). Venoarterial ECMO was used in 51.3%, often combined with intraaortic balloon pump or Impella (Abiomed). The ECMO group exhibited greater preoperative acuity, with higher lactate, creatinine, and transaminases, and worse ventricular function. Mortality before any intervention was significantly higher with ECMO (30.0% vs 1.8%, P < .001). Among those undergoing intervention, hospital mortality was 52.4% in the ECMO group and 28.6% without ECMO (P < .001). Seven patients received advanced therapy (concomitant durable left ventricular assist device and VSD repair, n = 3; reoperative left ventricular assist device after VSD repair, n = 3; and heart transplant, n = 1) with mortality of 28.6%. Multivariable analysis identified requirement of ECMO support, lactate ≥3 mmol/L, and left ventricular ejection fraction <50% as independent predictors of mortality. CONCLUSIONS: Ischemic VSD often necessitates tMCS, with venoarterial ECMO support in nearly half of cases. Although the outcomes remain guarded, advancements in tMCS technology, patient selection, and comprehensive approach are crucial in this challenging population.
引用
- Ohira S, Kai M, Tanaka D, et al. Contemporary Outcomes of Temporary Mechanical Circulatory Support Use in Ischemic Ventricular Septal Defect: A US Multicenter Analysis. Ann Thorac Surg. 2026. PMID: 42336080. doi:10.1016/j.athoracsur.2026.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。